N-(苯甲基)亚氨基二碳亚氨基二酰胺 | 18030-95-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(苯甲基)亚氨基二碳亚氨基二酰胺
• 英文名称: Benzylbiguanide
• 英文别名: N-benzylimidodicarbonimidic diamide；1-benzyl-biguanide；1-benzylbiguanide；N-benzylbiguanide；EGL-6M；1-Benzyl-biguanid；2-Benzyl-1-(diaminomethylidene)guanidine
• CAS: 18030-95-0
• 化学式: C₉H₁₃N₅
• 分子量: 191.236
• InChiKey: IBWXAMPUVRBFIS-UHFFFAOYSA-N

物化性质

• 沸点：
  315.4±35.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-a]吡啶-3-甲酸乙酯 、 N-(苯甲基)亚氨基二碳亚氨基二酰胺 在 sodium methylate 作用下， 以 甲醇 为溶剂， 以26%的产率得到N-Benzyl-6-imidazo[1,2-a]pyridin-3-yl-[1,3,5]triazine-2,4-diamine
  参考文献：
  名称：

  Synthesis and cardiotonic activity of 2,4-diamino-1.3,5-triazines

  摘要：

  DOI：

  10.1016/0223-5234(89)90171-2
• 作为产物：
  描述：

  二聚氰胺 、 苄胺 在 盐酸 作用下， 以 甲苯 、 水 为溶剂， 反应 7.25h， 以56%的产率得到N-(苯甲基)亚氨基二碳亚氨基二酰胺
  参考文献：
  名称：

  Synthesis and In Vitro AMPK Activation of Cycloalkyl/Alkarylbiguanides with Robust In Vivo Antihyperglycemic Action

  摘要：

  这项工作描述了设计、一步合成以及一系列十种脂环和芳香（烷基+芳基：烷芳基）双胍类似物（与二甲双胍和苯乙双胍类似物）的体外、体内和体外抗糖尿病评价。设计是通过同位素替代、链环转化以及较低和较高同系物策略构思的。所有化合物均以晶体形式获得，并根据其光谱数据（NMR和质谱）确认了其结构，通过微量分析确定了其纯度。化合物在体外被评估为AMP激活蛋白激酶（AMPK）的激活剂。结果表明，化合物4、5和6与二甲双胍相比显示出类似或甚至更好的效果。使用AMPK的调节亚基γ进行对接分析，显示出与核苷酸结合口袋的多个相互作用。在小鼠糖尿病实验模型中，对化合物4-6进行了50mg/kg的单剂量体内评价。结果显示血浆葡萄糖水平显著下降（-40%）。选择化合物6进行口服葡萄糖耐量试验，显示出与二甲双胍类似的抗高血糖效果。体内结果表明，化合物4-6可能有效治疗实验性T2DM。

  DOI：

  10.1155/2017/1212609

文献信息

• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASES OR INFLAMMATORY DISEASES, CONTAINING BIGUANIDE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT
  申请人：THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20170333370A1

  公开（公告）日：2017-11-23

  The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-α, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

  本发明涉及一种大叶腺苷衍生物化合物，能够有效预防和治疗免疫性疾病。根据本发明的大叶腺苷衍生物化合物抑制了炎性细胞因子IL-17和TNF-α的产生，增加了具有免疫调节功能的调节性T细胞的活性，并在动物模型中展现出优秀的治疗效果。因此，这种基于大叶腺苷衍生物的化合物可以用作免疫抑制剂或药物组合物，能够预防或治疗由免疫反应失调引起的各种免疫性疾病，如自身免疫性疾病、炎症性疾病和移植排斥等。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2004069823A1

  公开（公告）日：2004-08-19

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶的技术。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION
  申请人：Dietz Ulrich

  公开号：US20130090488A1

  公开（公告）日：2013-04-11

  The present invention is directed to solubilizing compounds, a device and a method for solubilizing and removing carboxylic acids and especially fatty acids from oils, fats, aqueous emulsion, aqueous media and organic solutions. Devices utilizing the inventive method shall be used for separating carboxylic acids from oils, fats, aqueous emulsion, lipophilic media or organic solutions, respectively by preparing an aqueous micro- or nanoemulsion of the carboxylic acids especially the fatty acids and the solubilizing compound which contains at least one amidino and/or gianidino group. Solubilization effects of solubilizing compounds combined with the inventive use of separation methods for carboxylic acids can be used to treat persons in need of removal of fatty acids or analyze carboxylic acids from blood or process other solutions in food, pharmacy, chemistry, bio fuel industry or other industrial processings.

  本发明涉及溶解化合物、用于从油、脂肪、水乳液、水介质和有机溶液中溶解和去除羧酸，特别是脂肪酸的装置和方法。采用本发明方法的装置将用于通过制备羧酸特别是脂肪酸和含有至少一种氨基甲酰基和/或肼基团的溶解化合物的水微观或纳米乳液，分离油、脂肪、水乳液、亲脂性介质或有机溶液中的羧酸。溶解化合物的溶解效果与本发明所述的羧酸分离方法相结合，可用于治疗需要去除脂肪酸或从血液中分析羧酸或处理食品、药品、化学、生物燃料工业或其他工业加工过程中的其他溶液的人员。
• BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
  申请人：HANALL BIOPHARMA CO., LTD.

  公开号：US20150376123A1

  公开（公告）日：2015-12-31

  A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

  本发明提供了一种N4-N5取代的biguanide衍生物化合物，其由公式1表示，或其药学上可接受的盐，以及其制备方法和包含其作为活性成分的药物组合物。与传统药物相比，该biguanide衍生物可能在低剂量下表现出对AMPK的激活和抑制癌细胞增殖的优异效果，因此可能有助于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠状动脉疾病、骨质疏松症、多囊卵巢综合症、代谢综合征、癌症等。